Argenica Therapeutics Ltd (AGN) AI Stock Analysis

• Market Cap: AU$28.90M
• Dividend Yield: N/A
• Average Volume (3M): 511.75K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.53
• Revenue Growth: N/A
• EPS Growth: -5.68%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.03
• Shares Outstanding: 128,456,710
• 10 Day Avg. Volume: 288,263
• 30 Day Avg. Volume: 511,745
• PEG Ratio: -2.24
• Price to Book (P/B): 13.39
• Price to Sales (P/S): 30.16
• P/FCF Ratio: -16.99
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$0.64
• Price Target Upside: 190.91% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 0.1
• Revenue Forecast (FY): AU$27.40M

• Rating: 43 Neutral
• Price Target: AU$0.23 ▲(3.18% Upside)
• Action: Reiterated Date: 02/26/26
• Date: Action: Reiterated 02/26/26

The score is driven down mainly by weak financial performance (large ongoing losses, material cash burn, and declining equity despite no debt) and bearish technical signals (price below key moving averages with negative MACD). Valuation is also constrained by negative earnings (negative P/E) and no dividend support.

Positive Factors

Zero debt

Zero reported debt reduces refinancing and interest burden risk, giving management flexibility to fund R&D via equity, grants, or partnerships. For an early-stage biotech, a debt-free balance sheet lengthens optionality and protects operations against credit market stress.

Top-line growth

Sequential revenue growth indicates progressing commercial traction or non-dilutive funding (grants/milestones) and provides external validation of the company’s activities. Sustained top-line expansion supports partnership, licensing, or milestone-based financing options over the medium term.

Improving free cash flow trend

Year-over-year improvement in free cash flow signals better operational efficiency or expense control. While still negative, a durable improvement trend can extend runway, lower immediate dilution risk and enable more predictable planning for clinical milestones and partner discussions.

Negative Factors

Large cash burn

Sustained negative operating and free cash flow near -5.7M annually constitutes a structural cash burn that will require external funding to sustain operations and trials. Persistent burn increases dilution risk, compresses runway for clinical programs, and can force suboptimal financing or partnership timing.

Deep negative margins

Very large negative net and EBIT margins show the cost base far exceeds current revenue, indicating no near-term path to profitability. Structurally negative margins make the business dependent on successful clinical outcomes or continual capital raises, limiting internal value capture.

Declining shareholder equity

A sharp drop in shareholder equity reflects capital consumption from losses and reduces the balance-sheet buffer. This erosion heightens reliance on external capital, increases the probability of dilutive financings, and weakens financial flexibility to fund development programs independently.

Argenica Therapeutics Ltd Business Overview & Revenue Model

Company Description

Argenica Therapeutics Limited engages in the research and development of a neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate use to protect brain cells and reduce cell death during a stroke and other types of neural injuries. The company was incorporated in 2019 and is based in Nedlands, Australia.

How the Company Makes Money

Argenica Therapeutics makes money primarily through the development and commercialization of its neuroprotective therapeutic products. The company's revenue model includes securing funding through partnerships with larger pharmaceutical companies, grants, and potential licensing agreements for its core technologies. As a biotech firm, Argenica is focused on advancing its product pipeline through clinical trials to achieve regulatory approval, which can lead to revenue generation through product sales, licensing, or strategic partnerships with established players in the pharmaceutical industry. Additionally, the company may benefit from government or private sector grants aimed at fostering innovation in medical treatments.

Argenica Therapeutics Ltd Financial Statement Overview

Summary

Early-stage biotech profile: revenue is growing (~3.2M in 2025 vs. ~2.6M in 2024), but profitability is very weak with deeply negative margins and ongoing large net losses. Balance sheet has no debt, but equity fell sharply (~14.0M to ~7.2M), and cash flow remains meaningfully negative (FCF about -5.7M in 2025), implying continued reliance on external funding.

Income Statement

Revenue has scaled meaningfully in recent years (2025 annual revenue of ~3.2M vs. ~2.6M in 2024), but profitability remains weak with consistently large operating losses and net losses. Net margin is deeply negative in 2025 (about -223%) and EBIT margin is also strongly negative, indicating the cost base is still far ahead of the current revenue run-rate. Strength: improving top-line trajectory; weakness: no clear path to operating breakeven in the reported periods.

Balance Sheet

The balance sheet is conservatively levered with zero debt reported across periods, which reduces financial risk and refinancing pressure. However, shareholder equity declined sharply from 2024 to 2025 (from ~14.0M to ~7.2M), and returns on equity are materially negative (about -99% in 2025), reflecting continued losses and likely capital consumption. Strength: no leverage; weakness: weakening equity base and persistent value dilution risk if losses continue.

Cash Flow

Cash generation remains negative with operating cash flow and free cash flow both around -5.7M in 2025 (and -5.1M in 2024), indicating ongoing cash burn to fund operations. While free cash flow growth shows improvement in 2025 versus 2024, cash flow still does not cover losses in a way that signals self-funding operations. Strength: some year-over-year improvement in free cash flow trend; weakness: sustained negative operating and free cash flow implies continued funding needs.

Breakdown	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	3.21M	2.60M	0.00	259.10K	296.07K
Gross Profit	3.21M	2.60M	1.75M	259.10K	296.07K
EBITDA	0.00	-1.90M	-4.81M	-4.09M	-1.33M
Net Income	-7.17M	-5.48M	-4.82M	-4.09M	-1.03M
Balance Sheet
Total Assets	11.04M	16.38M	9.54M	9.04M	7.27M
Cash, Cash Equivalents and Short-Term Investments	10.56M	15.91M	9.34M	8.91M	7.14M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	3.80M	2.43M	1.87M	735.91K	425.72K
Stockholders Equity	7.24M	13.95M	7.67M	8.31M	6.85M
Cash Flow
Free Cash Flow	-5.70M	-5.06M	-3.30M	-3.36M	-1.05M
Operating Cash Flow	-5.70M	-5.06M	-3.30M	-3.36M	-1.05M
Investing Cash Flow	0.00	50.00K	-50.00K	0.00	0.00
Financing Cash Flow	346.90K	11.63M	3.73M	5.13M	7.85M

Argenica Therapeutics Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.22
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:AGN, the sentiment is Negative. The current price of 0.22 is below the 20-day moving average (MA) of 0.26, below the 50-day MA of 0.28, and below the 200-day MA of 0.44, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 27.53 is Positive, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:AGN.

Argenica Therapeutics Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AVE	48 Neutral	AU$36.73M	-7.14	-143.71%	―	306.88%	―
NC6	47 Neutral	AU$24.16M	-9.61	-1651.76%	―	-100.00%	2.86%
RAC	44 Neutral	AU$437.90M	-44.88	-27.89%	―	―	67.26%
AGN	43 Neutral	AU$28.90M	-2.95	-67.68%	―	―	-5.68%
ATH	41 Neutral	AU$87.00M	-6.67	-42.68%	―	―	63.46%
1AD	37 Underperform	AU$10.20M	-2.38	-628.72%	―	―	31.87%

Argenica Therapeutics Ltd Corporate Events

Argenica Widens Half-Year Loss as ARG-007 Stroke Trial Spending Climbs

Argenica Therapeutics reported a sharp increase in half-year loss to $3.8 million as it accelerated clinical and development spending on its neuroprotective drug pipeline. Revenue fell 77% to $720,169, primarily due to timing differences in recognition of the Australian R&D tax incentive rebate, while net tangible assets per share dropped to 2.68 cents.

Research and development expenses rose to $3.0 million, driven mainly by the Phase 2 trial of ARG-007 in ischemic stroke patients and other non-clinical studies. Net operating cash outflows widened to $5.5 million despite non-dilutive government grant and R&D rebate inflows, and the company ended the period with $5.0 million in cash and no interim dividend, underscoring ongoing funding needs as it advances its clinical program.

The most recent analyst rating on (AU:AGN) stock is a Buy with a A$0.64 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.

Argenica Wins EMA Paediatric Waiver, Streamlining EU Pathway for Stroke Drug ARG-007

Argenica Therapeutics has secured a full product-specific paediatric waiver from the European Medicines Agency for its lead neuroprotective candidate ARG-007 in acute ischaemic stroke, removing the obligation to conduct paediatric clinical trials for this rare condition in children. The decision, recommended by the EMA’s Paediatric Committee, allows the company to advance ARG-007 through the European approval pathway for adult stroke without paediatric studies, significantly streamlining development, cutting cost and time, and reducing regulatory complexity. This milestone strengthens Argenica’s global regulatory strategy, accelerates its path toward a potential EU marketing authorisation for ARG-007 in adult stroke patients, and is expected to enhance the drug’s attractiveness to prospective pharmaceutical partners by de-risking the European development program.

The most recent analyst rating on (AU:AGN) stock is a Buy with a A$0.64 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.

Argenica’s AI Analysis Confirms ARG-007 Efficacy in Severe Stroke, Paving Way for Phase 2b Trial

Argenica Therapeutics has reported new AI-driven post-hoc analysis from its Phase 2 acute ischaemic stroke trial showing statistically significant and clinically meaningful efficacy of its lead drug ARG-007 in patients with severe stroke, a group with the greatest unmet need and typically poorer outcomes after thrombectomy. Building on these results, along with earlier safety and efficacy signals, the company plans to advance into a targeted Phase 2b trial using a precision medicine strategy that optimises patient selection based on stroke severity and AI-enabled diagnostic tools, while recent in vitro testing requested by the FDA confirmed ARG-007 does not interfere with the clot-busting agent tenecteplase, reducing regulatory risk and supporting its use alongside standard-of-care therapies; with $5.0 million in cash at 31 December 2025, expected R&D tax rebates and grant funding, and further research into other neurological indications backed by more than $4 million in non-dilutive funding, Argenica is reinforcing its clinical and financial position in the neuroprotection space.

The most recent analyst rating on (AU:AGN) stock is a Sell with a A$0.24 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.

Argenica Therapeutics Announces Departure of Director Di Angus

Argenica Therapeutics has notified the ASX that director Di Angus ceased to be a director of the company effective 31 December 2025, in line with listing rule disclosure requirements. The filing records that Angus holds 500,000 unlisted options with an exercise price of $0.93 expiring on 31 May 2027, and confirms there are no additional indirect security interests or related contracts disclosed in connection with her departure.

The most recent analyst rating on (AU:AGN) stock is a Hold with a A$0.27 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.

Argenica Chair Steps Down as Biotech Prepares for Next Growth Phase

Argenica Therapeutics has announced the resignation of Non-Executive Chair and Director Dianne Angus, effective at the end of December, after two years on the board during which she helped steer the company through early-stage clinical development, including a successful Phase 2 trial in acute ischaemic stroke and the strategic expansion of its therapeutic pipeline. The board credited Angus with embedding robust governance, risk management and compliance frameworks suited to a clinical-stage biotech and said it has begun searching for a new chair with strong global business development and strategic partnering experience to support Argenica’s planned international growth, signalling an intensifying focus on commercialisation and overseas expansion as the company advances its neuroprotective candidates.

The most recent analyst rating on (AU:AGN) stock is a Buy with a A$0.63 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.

Argenica’s ARG-007 Shows Promising Results in Severe Stroke Patients

Argenica Therapeutics has announced significant findings from an AI-driven reanalysis of its Phase 2 trial, demonstrating the efficacy of its drug ARG-007 in improving outcomes for severe stroke patients. The analysis revealed that ARG-007 significantly improves functional outcomes and reduces infarct volumes in patients with severe strokes, presenting a substantial commercial opportunity and guiding the design of a precision medicine approach for future trials.

The most recent analyst rating on (AU:AGN) stock is a Buy with a A$0.63 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.